Ro 5-3335 was identified in a screen for inhibitors of the RUNX1-CBFbeta interaction. It represses RUNX1/CBFB-dependent transactivation in reporter assays and runx1-dependent hematopoiesis in zebrafish embryos.1 Ro 5-3335 slows disease progression in various models including acute kidney injury2, acute myocardial infarction3 and osteoarthritis4 among others5. It synergizes with an HDAC inhibitor enhancing the activation of latent HIV-1 in both cell lines and patient PBMCs.6
* VAT and and shipping costs not included. Errors and price changes excepted